{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Neutrophils"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"}],"units":"Participants"}],"title":"Platelets"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"title":"Prothrombin Time"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Activated Partial Thromboplastin Time"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"title":"INR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"title":"Fibrinogen"}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"Laboratory parameters included hematological and biochemistry parameters. Hematological parameters included neutrophils, platelets, prothrombin time, activated partial thromboplastin time, INR, fibrinogen. Number of participants with hematological abnormalities by grades (as per Common Terminology Criteria for Adverse Events (CTCAE version 4.03) were reported. Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. Participants with a grade shift of 3 or more from baseline are reported in this outcome measure.","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment and had at least 1 post-baseline safety assessment. Here, \"Number Analyzed\" signifies number of participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"From Baseline up to 30 days following the last dose of study treatment (maximum up to 21 months)","title":"Number of Participants With Shift From Baseline in Clinical Laboratory - Hematology Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}